Analyst Swayampakula Ramakanth of H.C. Wainwright reiterated a Buy rating on Corcept Therapeutics, retaining the price target of $145.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Swayampakula Ramakanth has given his Buy rating due to a combination of factors that include the anticipated growth driven by new product launches and strategic measures to address current supply challenges. Despite the recent revenue miss attributed to supply chain issues with Korlym, Corcept Therapeutics is taking steps to improve this situation by bringing a second specialty pharmacy online by the end of 2025. This move is expected to enhance supply chain efficiency and meet the growing demand.
Moreover, the upcoming launch of relacorilant, anticipated in early 2026, is a significant factor in the positive outlook. Relacorilant is expected to receive approval for hypercortisolism and is projected to become a preferred choice over existing products, contributing substantially to revenue from 2027 onwards. Additionally, promising results from the ROSELLA study in platinum-resistant ovarian cancer further bolster confidence in relacorilant’s potential, with a new indication expected to come online in mid-2026. These developments, coupled with proactive measures to prevent supply issues, underpin the Buy rating for Corcept Therapeutics.
Ramakanth covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Ocugen, and ALX Oncology Holdings. According to TipRanks, Ramakanth has an average return of 6.5% and a 38.92% success rate on recommended stocks.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $77.00 price target.